ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3045 participants.

Also called NCT02619760

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 3,045 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02619760
Other papers using this trial's data
  • Details on the effect of very short dual antiplatelet therapy after drug-eluting stent implantation in patients with high bleeding risk: insight from the STOPDAPT-2 trial Cardiovascular intervention and therapeutics, 2021-01 DOI, PubMed 32086787
  • Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial JAMA, 2019-06-25 DOI, PubMed 31237644, PMC6593641 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02619760. Randomized; no masking; primary purpose treatment. Start 2015-12 (actual); primary completion 2018-12-08 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study
Acronym
STOPDAPT-2
Intervention (Drug)
1-month DAPT
Intervention (Drug)
12-month DAPT
Lead sponsor
Kyoto University, Graduate School of Medicine (class: other)

Record details

Record id
cardio:ct-nct02619760
Content hash
82f8fbffe851133f5aab1e8eae60c8c3109fdea1cdf77505aab855848e6388c7